Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study

Citation

Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. 2014.

Publication Year2014
PMID25499939

Study Details

Study DesignMulticenter randomized placebo-controlled trial
Evidence LevelHuman clinical evidence
Sample Size116

Results

Both tested Xuezhikang doses lowered non-HDL-C and LDL-C versus placebo in the study abstract.

Limitations

Short duration and selected population limit generalization.

Related Product

  • Xuezhikang Capsule